Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz Jared Holz, Mizuho, ...

Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

The Danish drug company said an experimental weight-loss shot helped patients lose over one-fifth of their bodyweight. Novo's U.S. and [Europe-listed s ...

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

Novo Nordisk just got a reality check. The company's latest trial for a higher-dose Wegovy showed it helps patients shed more ...

Health-care companies rose as traders rotated back into the sector amid optimism about blockbuster drugs. Novo Nordisk shares rose by more than 8% for one of their biggest gains in recent years after ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

Novo Nordisk on Friday reported strong early-stage results for its once-a-week obesity drug. Before the open, Novo Nordisk stock jumped while Eli Lilly fell. In the phase 1b/2a clinical trial, obese ...